The use of antidepressants, especially selective serotonin reuptake inhibitors, during the final two trimesters of pregnancy was associated with increased risk for autism spectrum disorder in children, according to an article published online by JAMA Pediatrics.
Antidepressants (ADs) are widely used during pregnancy to treat depression. Autism spectrum disorder (ASD) is a neurodevelopmental syndrome characterized by altered communication, language and social interaction and by particular patterns of interests and behaviors. Few studies have investigated the effect of AD use during pregnancy on the risk of ASD in children.
The authors identified 4,724 infants (3.2 percent) who were exposed to ADs in utero; 4,200 (88.9 percent) infants were exposed during the first trimester and 2,532 (53.6 percent) infants were exposed during the second and/or third trimester. There were 31 infants (1.2 percent) exposed to ADs during the second and/or third trimester diagnosed with ASD and 40 infants (1.0 percent) exposed during the first trimester diagnosed with ASD, according to the results.
The use of ADs during the second and/or third trimester was associated with an 87 percent increased of ASD (32 exposed infants), while no association was observed between the use of ADs during the first trimester or the year before pregnancy and the risk of ASD.
Results indicate the increased risk of ASD was observed with selective serotonin reuptake inhibitors (22 exposed infants) and with the use of more than one class of AD during the second and/or third trimester (five exposed infants). In children of mothers with a history of depression, the use of ADs during the second and/or third trimester was associated with an increased risk for ASD in the study (29 exposed infants).
The authors suggest several mechanisms may account for the increased risk of ASD associated with maternal use of ADs during pregnancy. Limitations to the study include its use of prescription filling data, which may not reflect actual use. The data also contained no information on maternal lifestyle.
"Further research is needed to specifically assess the risk of ASD associated with antidepressant types and dosages during pregnancy," the study concludes.
http://archpedi.jamanetwork.com/article.aspx?articleid=2476187
Edited
Latest News
A way to modulate scarring…
By newseditor
Posted 03 Oct
New blood test could be an…
By newseditor
Posted 03 Oct
Neuronal pathways involved…
By newseditor
Posted 02 Oct
Physiological role of 5-for…
By newseditor
Posted 02 Oct
Master copper regulator in…
By newseditor
Posted 01 Oct
Other Top Stories
Reversing fatty liver disease!
Read more
Reduced response rate in neural stem cells in Huntington's Disease…
Read more
Linking autism risk to fever during pregnancy!
Read more
Parkinson's could start in gut endocrine cells!
Read more
Mechanism of antidepressant ketamine's long term effect unraveled!
Read more
Protocols
Droplet-based functional CR…
By newseditor
Posted 03 Oct
Multi-peptide characterizat…
By newseditor
Posted 24 Sep
Nanoplasmonic aptasensor fo…
By newseditor
Posted 20 Sep
Modeling the atrioventricul…
By newseditor
Posted 11 Sep
Modeling the atrioventricul…
By newseditor
Posted 11 Sep
Publications
Intracellular Ebola virus n…
By newseditor
Posted 03 Oct
Host-microbe serotonin meta…
By newseditor
Posted 03 Oct
Biliverdin Reductase-A inte…
By newseditor
Posted 03 Oct
Axon guidance during mouse…
By newseditor
Posted 03 Oct
A new clinical age of aging…
By newseditor
Posted 03 Oct
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar